View in EDS

Circulating tumor DNA as a prognostic biomarker in adjuvant nivolumab therapy for high-risk muscle-invasive urothelial carcinoma: insights from CheckMate 274 and beyond.

Saved in:
Bibliographic Details
Title: Circulating tumor DNA as a prognostic biomarker in adjuvant nivolumab therapy for high-risk muscle-invasive urothelial carcinoma: insights from CheckMate 274 and beyond.
Authors: Yajima S; Department of Urology, National Cancer Center Hospital East, Chiba, Japan., Masuda H; Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
Source: Translational andrology and urology [Transl Androl Urol] 2026 Apr 27; Vol. 15 (4), pp. 95. Date of Electronic Publication: 2026 Apr 22.
Publication Type: Editorial; Comment
Journal Info: Publisher: AME Pub Country of Publication: China NLM ID: 101581119 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2223-4691 (Print) Linking ISSN: 22234683 NLM ISO Abbreviation: Transl Androl Urol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42164377
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Circulating tumor DNA as a prognostic biomarker in adjuvant nivolumab therapy for high-risk muscle-invasive urothelial carcinoma: insights from CheckMate 274 and beyond.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yajima+S%22">Yajima S</searchLink>; Department of Urology, National Cancer Center Hospital East, Chiba, Japan.<br /><searchLink fieldCode="AU" term="%22Masuda+H%22">Masuda H</searchLink>; Department of Urology, National Cancer Center Hospital East, Chiba, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101581119%22">Translational andrology and urology</searchLink> [Transl Androl Urol] 2026 Apr 27; Vol. 15 (4), pp. 95. <i>Date of Electronic Publication: </i>2026 Apr 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Editorial; Comment
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22AME+Pub%22">AME Pub </searchLink><i>Country of Publication: </i>China <i>NLM ID: </i>101581119 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2223-4691 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222234683%22">22234683 </searchLink><i>NLM ISO Abbreviation: </i>Transl Androl Urol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42164377
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.21037/tau-2026-1-0117
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 95
    Titles:
      – TitleFull: Circulating tumor DNA as a prognostic biomarker in adjuvant nivolumab therapy for high-risk muscle-invasive urothelial carcinoma: insights from CheckMate 274 and beyond.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yajima S
      – PersonEntity:
          Name:
            NameFull: Masuda H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 04
              Text: 2026 Apr 27
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2223-4691
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Translational andrology and urology
              Type: main
ResultId 1